Navigation Links
Innovative Psoriasis Treatment PSORENT(R) Announces Healthcare Cost Savings Potential Consistent with President Obama's Announcement on Healthcare Reform
Date:6/25/2009

PRINCETON, N.J., June 25 /PRNewswire/ -- "Congratulations President Obama on your agreement with large pharmaceutical companies to cut prescription costs for the elderly," says Mark D. Steele, president of NeoStrata Company, Inc. "We thought you should know that you have a little company in New Jersey that's done the same for psoriasis sufferers of all ages."

Mr. Steele is speaking about NeoStrata Company, Inc., and the submission of their findings from a recent clinical study announcing the significant cost-savings associated with their non-prescription, psoriasis medicine PSORENT(R) psoriasis topical solution.

Earlier this week, NeoStrata Company, Inc. submitted results for publication from an 18 week long clinical study demonstrating how psoriasis patients can save hundreds of dollars a year with their novel, non-prescription psoriasis therapy that has outperformed the leading non-steroidal prescription topical in treating the redness and scaling of psoriasis.

"In these economic times we are thrilled to be able to offer a psoriasis medicine that does not require a prescription, is significantly less expensive than most prescription drugs for psoriasis, and performs as well or better than a leading prescription medication," says Mr. Steele.

"This is not a story you hear very often, and as a small company," he explains, "we are just very excited and proud of this new psoriasis therapy and of the value it presents to patients."

NeoStrata Company, Inc. has spent the last few years developing PSORENT(R) and conducting clinical studies and after just receiving the cost savings analyses agrees the timing couldn't be better in tune with what's happening in the economy.

"As a small company," Steele explains, "we have created an affordable and preferable treatment for psoriasis that can save patients hundreds and thousands of dollars in healthcare costs, and we want you to know that we are with you, Mr. President."

About PSORENT(R)

PSORENT(R) is a new topical solution that has the proven efficacy of a prescription medication but is available as an OTC. This aesthetically advanced, quick-drying solution is highly effective, easy and pleasant to use, and has a patient satisfaction rating of nearly 90%.

About NeoStrata

NeoStrata Company, Inc., located in Princeton, NJ develops and markets a comprehensive range of clinically-proven, dermatologist developed skin care products. These advanced therapeutic and cosmetic dermatological products are available worldwide through consumer outlets, physicians' offices and spas.

More information is available at www.neostrata.com and www.psorent.com.


'/>"/>
SOURCE NeoStrata Company, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
2. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
3. Oculus Innovative Sciences to Present at 4th Annual BIO InvestorForum Conference
4. Surgeons Develop Innovative Life-Saving Treatments to Correct Massive Bleeding in Trauma Patients
5. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
6. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
7. Innovative Brain Scanning for Alzheimers Screening Unveiled
8. Gates Foundation Seeks Proposals for Innovative Global Health Research
9. In Blood Vessel Stents, Innovative Materials Allow Better Control, Delivery of Gene Therapy
10. Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times
11. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
(Date:6/23/2016)... June 23, 2016 The Biotechnology ... continues to present great opportunities to investors. Stock-Callers.com assesses ... Intrexon Corp. (NYSE: XON ), Vertex Pharmaceuticals ... (NASDAQ: ARNA ), and Regeneron Pharmaceuticals Inc. ... stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):